The National Institute for Health and Care Excellence (NICE) and NHS England will use standard systems already in place to measure access to treatments. In addition, NICE and NHS England have committed to review the impact of the changes to the arrangements for the assessment and adoption of new treatments three years after their implementation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"} , "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"} , "dateOfAnswer" : {"_value" : "2017-04-20", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-04-20T10:38:33.997Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-04-13", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs: Licensing"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what factors will be measured to monitor patient access to treatment after the introduction of the NICE and NHS England joint changes to technology appraisals and highly specialised technologies reforms.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"} } , "tablingMemberConstituency" : {"_value" : "Scunthorpe"} , "tablingMemberPrinted" : [{"_value" : "Nic Dakin"} ], "uin" : "70639"} , {"_about" : "http://data.parliament.uk/resources/720542", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/720542/answer", "answerText" : {"_value" : "
The changes to technology appraisals and highly specialised technologies are being implemented for topics with a first evidence submission to the National Institute for Health and Care Excellence (NICE) after 1 April. It is therefore too soon for products under the new arrangements to have received their final guidance from NICE.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"} , "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"} , "dateOfAnswer" : {"_value" : "2017-04-20", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-04-20T10:40:21.7Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-04-13", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs: Licensing"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment has been made of whether there have been delays to patient access to treatment as a result of the proposals being implemented by the NICE and NHS England joint changes to technology appraisals and highly specialised technologies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"} } , "tablingMemberConstituency" : {"_value" : "Scunthorpe"} , "tablingMemberPrinted" : [{"_value" : "Nic Dakin"} ], "uin" : "70640"} , {"_about" : "http://data.parliament.uk/resources/714576", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/714576/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing robust, evidence based guidance for the National Health Service on the clinical and cost effectiveness of drugs and other treatments. NICE is currently appraising nivolumab for use in the treatment of relapsed or refractory classical Hodgkin lymphoma. NICE published its draft guidance for consultation on 14 March and stakeholders had until 3 April to comment. NICE currently expects to publish final guidance in July 2017.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"} , "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"} , "dateOfAnswer" : {"_value" : "2017-04-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-04-18T13:47:53.41Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-03-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nivolumab: Hodgkin Lymphoma"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment his Department has made of the clinical benefits of nivolumab for patients with relapsed or refractory classical Hodgkin lymphoma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"} } , "tablingMemberConstituency" : {"_value" : "Scunthorpe"} , "tablingMemberPrinted" : [{"_value" : "Nic Dakin"} ], "uin" : "69561"} , {"_about" : "http://data.parliament.uk/resources/714578", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/714578/answer", "answerText" : {"_value" : "
NHS England has advised that there are two main drugs that are currently licensed for the treatment of patients who have failed standard therapies for their Hodgkin lymphoma; brentuximab and nivolumab.<\/p>
<\/p>
Brentuximab is currently available through the Cancer Drugs Fund for the treatment of patients with relapsed or refractory CD30 positive Hodgkin\u2019s lymphoma. The National Institute for Health and Care Excellence (NICE) is currently appraising brentuximab and expects to publish final guidance in May 2017.<\/p>
<\/p>
Nivolumab is licensed for patients with Hodgkin lymphoma who have progressed despite an autologous stem cell transplant and who have also received treatment with brentuximab. NICE is currently appraising nivolumab for use in this indication and expects to publish final guidance in July 2017. Nivolumab is not currently funded routinely in this indication.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"} , "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"} , "dateOfAnswer" : {"_value" : "2017-04-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-04-18T13:46:18.057Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-03-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Hodgkin Lymphoma"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the availability of treatment options for patients with classical Hodgkin lymphoma whose disease has progressed or not responded to standard of care treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"} } , "tablingMemberConstituency" : {"_value" : "Scunthorpe"} , "tablingMemberPrinted" : [{"_value" : "Nic Dakin"} ], "uin" : "69562"} , {"_about" : "http://data.parliament.uk/resources/714580", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/714580/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes it uses in the development of its guidance, which are developed through extensive engagement with stakeholders and periodically reviewed to ensure they remain appropriate. NICE has been able to recommend a number of drugs for the treatment of blood cancers for small patient populations through its technology appraisal programme.<\/p>
<\/p>
NICE has not yet published final guidance on the use of nivolumab for the treatment of relapsed or refractory classical Hodgkin lymphoma and stakeholders had until 3 April to comment on NICE\u2019s draft recommendations.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"} , "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"} , "dateOfAnswer" : {"_value" : "2017-04-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-04-18T13:44:19.907Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-03-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nivolumab"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what discussions his Department has had with NICE on that body's decision not to recommend nivolumab for treating relapsed or refractory classical Hodgkin lymphoma and the suitability of methods of appraisal used to assess blood cancer medicines which treat small patient populations.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"} } , "tablingMemberConstituency" : {"_value" : "Scunthorpe"} , "tablingMemberPrinted" : [{"_value" : "Nic Dakin"} ], "uin" : "69563"} , {"_about" : "http://data.parliament.uk/resources/712980", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/712980/answer", "answerText" : {"_value" : "
The Chief Medical Officer recommends that all children aged five-18 should get at least 60 minutes of moderate to vigorous physical activity each day.<\/p>
<\/p>
The Government published a Childhood Obesity Plan for Action in August 2016, which can be accessed here:<\/p>
https://www.gov.uk/government/publications/childhood-obesity-a-plan-for-action<\/a><\/p> <\/p> This plan states that for all primary school children, at least 30 minutes of physical activity should be delivered in school every day through active break times, Physical Education, extra curricular clubs, active lessons or other sport and physical activity events. Schools have the freedom to decide how to meet this expectation and which programmes, such as The Daily Mile, they choose to adopt.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
}
, "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"}
, "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"}
, "dateOfAnswer" : {"_value" : "2017-03-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-03-24T11:38:12.143Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-03-21", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Exercise: Children"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, whether he plans to launch the Daily Mile nationwide in England.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "68767"}
, {"_about" : "http://data.parliament.uk/resources/713017", "AnsweringBody" : [{"_value" : "Ministry of Justice"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/713017/answer", "answerText" : {"_value" : " This information is not held centrally.<\/p> <\/p>
<\/strong> Average waiting time in weeks for the disposal of Personal Independence Payment <\/strong>1<\/sup> appeals from receipt to outcome<\/strong>2<\/sup><\/strong> for the last four quarterly periods (January \u2013 December 2016) <\/strong><\/p><\/td><\/tr> <\/p><\/td> Doncaster <\/strong>3<\/sup><\/strong><\/p><\/td> England<\/strong><\/p><\/td><\/tr> January \u2013 March 2016<\/p><\/td> 21<\/p><\/td> 16<\/p><\/td><\/tr> April \u2013 June 2016<\/p><\/td> 19<\/p><\/td> 15<\/p><\/td><\/tr> July \u2013 September 2016<\/p><\/td> 15<\/p><\/td> 15<\/p><\/td><\/tr> October \u2013 December 2016<\/p><\/td> 15<\/p><\/td> 16<\/p><\/td><\/tr><\/tbody><\/table> <\/p> SSCS data are attributed to the hearing venue nearest to the appellant\u2019s home address. If the case goes to an oral hearing, the location of the Tribunal hearing venue is normally nearest to the appellant\u2019s home address. We cannot retrieve data based on the appellants actual address, but can produce reports detailing the numbers of cases that were dealt with at one of our Regional centres or heard at a specific venue.<\/p> <\/p> 1<\/sub> Personal Independence Payment (New Claim Appeals), which replaced Disability Living Allowance and was introduced on 8 April 2013, also includes Personal Independence Claims (Reassessments).<\/p> 2 <\/sub>Outcome: All appeals disposed of include those appeals disposed of with and without a tribunal hearing.<\/p> 3 <\/sub>Covers all appeals heard at the Doncaster Venue which serves appellants living in Scunthorpe.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/69", "label" : {"_value" : "Biography information for Sir Oliver Heald"}
}
, "answeringMemberConstituency" : {"_value" : "North East Hertfordshire"}
, "answeringMemberPrinted" : {"_value" : "Sir Oliver Heald"}
, "dateOfAnswer" : {"_value" : "2017-03-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-03-14T17:12:29.153Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "54"}
, "answeringDeptShortName" : {"_value" : "Justice"}
, "answeringDeptSortName" : {"_value" : "Justice"}
, "date" : {"_value" : "2017-03-07", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Personal Independence Payment: Appeals"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Justice, what the average waiting time is for an appeal against a mandatory reconsideration of a decision on personal independence payments in (a) Scunthorpe and (b) England for the last four periods for which figures are available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "66786"}
, {"_about" : "http://data.parliament.uk/resources/709064", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/709064/answer", "answerText" : {"_value" : " The Government is always exploring new ways to support disabled people, including those making PIP appeals. We have had a range of discussions with Motability and other relevant departments, and any announcement regarding the progress of these discussions will be made publicly by the Government in due course.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4017", "label" : {"_value" : "Biography information for Penny Mordaunt"}
}
, "answeringMemberConstituency" : {"_value" : "Portsmouth North"}
, "answeringMemberPrinted" : {"_value" : "Penny Mordaunt"}
, "dateOfAnswer" : {"_value" : "2017-03-15", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-03-15T14:16:27.37Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "29"}
, "answeringDeptShortName" : {"_value" : "Work and Pensions"}
, "answeringDeptSortName" : {"_value" : "Work and Pensions"}
, "date" : {"_value" : "2017-03-07", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Personal Independence Payment: Appeals"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Work and Pensions, pursuant to the Answer of 2 March 2017 to Question 64658, on personal independence payments, what options his Department is considering to better support disabled people with Motability vehicles who are waiting in excess of seven weeks for mandatory reconsiderations.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "66783"}
], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-ddpModified.=2017-04-26T18%3A45%3A35.590Z&min-date=2015-06-23&tablingMemberConstituency=Scunthorpe", "page" : 0, "startIndex" : 1, "totalResults" : 290, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|